EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

hVIVO plc (HVO) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of hVIVO plc £0.08, price £0.07, upside +21.4%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · GB

HP Thin data Sep 24, 2026

hVIVO plc

HVO · LSE

SpeculativeUpside exists, but weak quality makes the signal speculative.

✓Fair value £0.0818 · Undervalued (+21%)
!Quality 37/100
!Mixed Growth (revenue 5y +17.8 %/yr)
!Loss-making · -12.1% net margin (TTM)
!negative free cash flow
!Mixed vs. peers (4/10)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch hVIVO plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£0.3026 £0.0459 Fair Value £0.0818 Jul 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range £0.0459 – £0.3026 · fair‑value band £0.0620 – £0.0950 · the £0.0674 price screens below the £0.0818 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow hVIVO in your weekly email

Every Wednesday you see whether hVIVO is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services.

Show more

hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including virology, immunology and biomarker analysis, as well as assay development, sample analysis, and data interpretation. In addition, the company offers services combined with specialisms in infectious diseases, respiratory, and cardiometabolic therapeutical areas. Further, it provides pre­clinical and early clinical research services; sales and marketing services; data management; storage solutions; and statistics services, as well as drug development consultancy and services. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

Stock analysis

hVIVO plc (HVO) currently trades at £0.0674, while our model-based Fair Value estimate is £0.0818, implying the stock looks roughly 17.6% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of £0.1100 per share, and 1 of the 4 models we run sit above the £0.0674 price.

Bear case: the Dividend Discount group reads lowest at £0.0200, and 3 of the 4 models stay below the price. Evidence for this calculation is low.

Scenario range: £0.0620 (bear) to £0.0950 (bull), the price of £0.0674 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

hVIVO plc reported revenue of £46.8M in FY2025 versus £36.9M in FY2021, a compound +6.1%/yr. Reported net income was −£6.0M in FY2025.

Key figures

Market cap 46.2M GBX · P/S ratio 0.95 · EPS (TTM) £−0.0100 · Dividend yield 2.9% · Net margin −12.8% · Return on equity −14.5% · Return on assets (EBIT) 7.8% · Operating margin −17.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 47% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 21%, HVO screens cheaper than that median.

Fair Value models

Bear £0.0620 Fair Value £0.0818 Bull £0.0950
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Gordon GGM £0.0100 £0.0200 £0.0300 67
DDM Multi-Stage £0.0100 £0.0200 £0.0300 65
EV/EBITDA £0.0900 £0.1100 £0.1300 64
All 4 models by family
Dividend Discount
Gordon GGM £0.0100 £0.0200 £0.0300 67
DDM Multi-Stage £0.0100 £0.0200 £0.0300 65
Multiples
EV/EBITDA £0.0900 £0.1100 £0.1300 64
Asset-Based
NCAV (Graham) £0.0300 £0.0400 £0.0600 51

Open the full fair value analysis →

Notify me when HVO reaches fair value

Put HVO on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 41 · Market factors (momentum, volatility) 24

Profitability 9
Margins and returns on capital today
Quality Growth 5
Are margins and returns improving?
Cashflow 33
Earnings quality: real cash, not paper profit
Fin. Strength 78
Balance sheet, leverage, solvency risk
Investment 45
Disciplined investing over empire-building
Low Volatility 4
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 30
Distance to the 52-week high (market factor)
Net Issuance 80
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−25.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.8%
Start year 2020 (pandemic). Over 10 years: +18.6% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−50.7% (2020) → −0.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch HVO, get fair value alerts →

Compare hVIVO plc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside +24% · Top 25%
Profitability
Return on assets −3% · Below median
Net margin (TTM) −12% · Bottom 25%
Operating margin (TTM) −18% · Bottom 25%
Growth and dividend
Revenue growth −17% · Bottom 25%
Dividend yield (TTM) 2.9% · Above median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 1.57× · Cheaper than median
P/S (TTM) 1.21× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)62 · sector 0
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 8
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)58 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $658.52 $682.58 +4%
Danaher Corporation DHR $221.09 $207.76 −6%
WuXi AppTec Co 2359 HK$207.60 HK$228.36 +10%
Lonza Group LONN CHF 562.80 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $521.50 $495.84 −5%
Agilent Technologies, Inc A $167.26 $63.90 −62%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $247.46 $272.21 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

hVIVO plc · Fair Value
£0.0818 +18%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "hVIVO plc Fair Value". https://www.fairvalue-calculator.com/stock/HVO

Frequently asked questions

Is hVIVO plc (HVO) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of £0.0818 versus a price of £0.0674, about +21% upside (undervalued).
What is the fair value of HVO?
Our model-based fair value for hVIVO plc is £0.0818 (as of Sep 24, 2026), built from audited fundamentals. The current price: £0.0674.
What is the quality score of HVO?
hVIVO plc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for hVIVO plc (HVO)?
Our model-based price target is the fair value of £0.0818 (as of Sep 24, 2026) from 4 valuation models. Cautious scenario £0.0620, optimistic scenario £0.0950. It is a calculation from audited fundamentals, not an analyst target.
What is the hVIVO plc stock forecast for 2026?
Our models put fair value at £0.0818, about +21% upside versus a price of £0.0674 (undervalued). Cautious scenario £0.0620, optimistic scenario £0.0950. The calculation is refreshed regularly with new filings.
What is the revenue of hVIVO plc (HVO)?
hVIVO plc reported trailing-twelve-month revenue of about £49.7M (latest available figure, as of Sep 24, 2026).
Does hVIVO plc pay a dividend?
hVIVO plc currently shows a dividend yield of about 2.91% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of hVIVO plc (HVO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For hVIVO plc it is £0.0818 per share (as of Sep 24, 2026), against a price of £0.0674. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is hVIVO plc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, HVO trades below its calculated fair value: price £0.0674, fair value £0.0818, a gap of about +21% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HVO?
No. The price is what the market pays today (£0.0674); the fair value is what the company's own numbers justify (£0.0818). For hVIVO plc the two are £0.0144 per share apart. That gap is exactly why we show both numbers side by side.
How much is hVIVO plc worth?
The market values hVIVO plc at about 46.2M GBX (market capitalisation, as of Sep 24, 2026). Per share that is £0.0674; our models calculate a fair value of £0.0818 per share.
What do the bullish and bearish scenarios say about HVO?
Our models span a range for hVIVO plc: cautious scenario £0.0620, base £0.0818, optimistic £0.0950 per share (as of Sep 24, 2026, price £0.0674). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of hVIVO plc (HVO)?
Balance-sheet figures for hVIVO plc (as of Sep 24, 2026): return on equity −14.5%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is HVO from its 52-week high?
hVIVO plc trades at £0.0674, about 31% below its 52-week high of £0.0980 and 47% above the low of £0.0459 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of £0.0818 is for.
Which stocks are comparable to hVIVO plc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is hVIVO plc stock attractive at the current price?
The data as of Sep 24, 2026: price £0.0674, calculated fair value £0.0818 (+21%), Quality Score 37/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HVO calculated?
We run hVIVO plc through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £0.0818, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. hVIVO plc currently trades 21 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of hVIVO plc (HVO)?
The closing price on Sep 24, 2026 was £0.0674. Our model-based fair value is £0.0818, about +21% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with hVIVO plc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of hVIVO plc

How large is the market capitalisation of hVIVO plc (HVO)?
The market capitalisation of hVIVO plc is 46.2M GBX. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of hVIVO plc (HVO)?
The price-to-sales ratio of hVIVO plc is 0.95 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of hVIVO plc (HVO)?
Earnings per share at hVIVO plc are £−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of hVIVO plc (HVO)?
The dividend yield of hVIVO plc is 2.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of hVIVO plc (HVO)?
The net margin of hVIVO plc is −12.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of hVIVO plc (HVO)?
The return on equity (ROE) of hVIVO plc is −14.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of hVIVO plc (HVO)?
On an EBIT basis the return on assets of hVIVO plc is 7.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of hVIVO plc (HVO)?
The operating margin of hVIVO plc is −17.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at hVIVO plc (HVO)?
Revenue at hVIVO plc is growing −16.6% versus a year earlier (3y avg −1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at hVIVO plc (HVO)?
Earnings per share at hVIVO plc are growing −55.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does hVIVO plc (HVO) generate?
The free cash flow of hVIVO plc is −14.8M GBX (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does hVIVO plc (HVO) carry?
The net debt of hVIVO plc is 490K GBX (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch hVIVO plc in the live analysis

One click puts hVIVO plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.